Aim Major depressive disorder (MDD) is a prevalent psychiatric condition and vortioxetine
offers promising antidepressant effects due to its unique pharmacological profile. However …

Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA
designated psilocybin as a “breakthrough therapy” for the treatment of treatment-resistant …

Backgrounds Anxious depression (AD) has been extensively studied. However, fewer
studies have examined sex differences in the prevalence of suicide attempts among AD …

Hypochondriasis is a condition characterized by an unrealistic fear of having a serious
medical illness resulting in health anxiety. Currently, no evidence-based pharmacological …

Depressive symptoms are a customary finding in hospitalized patients, particularly those
who are undergoing long hospitalizations, underwent major surgical procedures or suffer …

Background Although vortioxetine demonstrates superior efficacy relative to placebo, there
is still a lack of robust evidence to determine whether it offers advantages over commonly …

Objective This study tried to observe clinical benefit of aripiprazole augmentation (ARPA)
treatment for major depressive disorder with anxious distress (MDDA) in routine practice …

文拉法辛(venlafaxine, VEN) 是一种新型抗抑郁药物, 能有效拮抗5-羟色胺(5-
hydroxytryptamine, 5-HT) 和去甲肾上腺素(norepinephrine, NE) 的再摄取 …

General practitioners observe a high prevalence of anxiety and depression symptoms.
Depressed or anxious patients frequently develop both conditions. The symptoms of both …

Objective This study tried to observe additional benefit of agomelatine (AGO) treatment for
major depressive disorder (MDD) in routine practice. Methods Retrospective chart review …